- Stocks
- Healthcare
- NASDAQ: AGIO

Price (delayed)

$55.23

Market cap

$3.86B

P/E Ratio

2.42

Dividend/share

N/A

EPS

$22.8

Enterprise value

$2.08B

The debt has declined by 7% year-on-year

Agios Pharmaceuticals's gross profit has decreased by 43% QoQ but it has increased by 31% YoY

The revenue has declined by 43% since the previous quarter but it has grown by 32% year-on-year

What are the main financial stats of AGIO

Market
Valuations
Earnings

Shares outstanding

69.94M

Market cap

$3.86B

Enterprise value

$2.08B

Price to earnings (P/E)

2.42

Price to book (P/B)

1.67

Price to sales (P/S)

33.08

EV/EBIT

1.31

EV/EBITDA

1.29

EV/Sales

17.9

Revenue

$116.1M

EBIT

$1.59B

EBITDA

$1.61B

Free cash flow

-$317.62M

Per share
Balance sheet
Liquidity

EPS

$22.8

Free cash flow per share

-$4.57

Book value per share

$33

Revenue per share

$1.67

TBVPS

$35.78

Total assets

$2.49B

Total liabilities

$191.8M

Debt

$103.61M

Equity

$2.3B

Working capital

$2.26B

Debt to equity

0.05

Current ratio

24.4

Quick ratio

24.2

Net debt/EBITDA

-1.11

Margins
Efficiency
Dividend

EBITDA margin

1,383.7%

Gross margin

98%

Net margin

1,367.1%

Operating margin

-313.7%

Return on assets

121.5%

Return on equity

170%

Return on invested capital

185.7%

Return on capital employed

66.4%

Return on sales

1,367.1%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Agios Pharmaceuticals stock price performed over time

Intraday

0.51%

1 week

-1%

1 month

3.5%

1 year

23.42%

YTD

27.46%

QTD

6.95%

How have Agios Pharmaceuticals's revenue and profit performed over time

Revenue

$116.1M

Gross profit

$113.83M

Operating income

-$364.17M

Net income

$1.59B

Gross margin

98%

Net margin

1,367.1%

The operating margin has dropped by 102% since the previous quarter but it has increased by 34% year-on-year

Agios Pharmaceuticals's gross profit has decreased by 43% QoQ but it has increased by 31% YoY

The revenue has declined by 43% since the previous quarter but it has grown by 32% year-on-year

Agios Pharmaceuticals's operating income has decreased by 15% from the previous quarter but it has increased by 12% YoY

What is Agios Pharmaceuticals's growth rate over time

What is Agios Pharmaceuticals stock price valuation

P/E

2.42

P/B

1.67

P/S

33.08

EV/EBIT

1.31

EV/EBITDA

1.29

EV/Sales

17.9

The P/B is 70% below the 5-year quarterly average of 5.5 and 68% below the last 4 quarters average of 5.2

The revenue has declined by 43% since the previous quarter but it has grown by 32% year-on-year

AGIO's P/S is 25% above its last 4 quarters average of 26.4 but 19% below its 5-year quarterly average of 40.7

How efficient is Agios Pharmaceuticals business performance

What is AGIO's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for AGIO.

How did Agios Pharmaceuticals financials performed over time

The total assets has surged by 192% since the previous quarter

AGIO's current ratio has surged by 190% year-on-year

The debt is 95% smaller than the equity

The debt to equity has shrunk by 81% QoQ and by 72% YoY

The debt has declined by 7% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.